Product Information
COSENTYX UNOREADY 300 MG/2 ML PEN (1 PEN) is a brand product labeled by Novartis Pharmaceuticals Corporation, priced at $4087.4067 per ML under NDC 00078107068. Its NADAC has been published 120 times since Jun 19, 2024.
Strength
300 mg/2mL
Manufacturer
Novartis Pharmaceuticals CorporationNDC
00078107068
Classification
Brand
Dosage Form
INJECTION
Route
SUBCUTANEOUS
Effective Date
9/23/2026
Active Ingredients
SECUKINUMABApproval Type
Biologic (BLA)
FDA Application
BLA125504On Market Since
1/21/2015
Pharmacological Classes
Price Statistics
The NADAC for COSENTYX UNOREADY 300 MG/2 ML PEN (1 PEN) has been published 120 times since Jun 19, 2024, and over the history we have for it it has risen 13.2%. The table below summarizes its recorded NADAC range and movement.
| Current price | $4087.4067 per ML |
|---|---|
| All-time high | $4105.5041 (May 13, 2026) |
| All-time low | $3591.8962 (Sep 18, 2024) |
| 52-week high | $4105.5041 |
| 52-week low | $3836.9198 |
| Median price | $3843.9345 |
| Average price | $3833.3372 |
| Largest weekly change | +7.0% (Jan 14, 2026) |
| Weeks tracked | 120 |
| Tracking since | Jun 19, 2024 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the secukinumab market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Novartis Pharmaceuticals Corporation manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
secukinumab market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Interleukin-17A Antagonist class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of COSENTYX UNOREADY 300 MG/2 ML PEN (1 PEN)?
The current National Average Drug Acquisition Cost (NADAC) for COSENTYX UNOREADY 300 MG/2 ML PEN (1 PEN), manufactured by Novartis Pharmaceuticals Corporation, is $4087.4067 per ML (NDC 00078107068), effective Sep 30, 2026.
How has the price of COSENTYX UNOREADY 300 MG/2 ML PEN (1 PEN) changed over time?
Over the history we have for it, the NADAC for COSENTYX UNOREADY 300 MG/2 ML PEN (1 PEN) has risen 13.2%. It has been tracked across 120 weekly CMS publications since Jun 19, 2024.
What are the highest and lowest recorded NADAC prices for COSENTYX UNOREADY 300 MG/2 ML PEN (1 PEN)?
Since Jun 19, 2024, the NADAC for COSENTYX UNOREADY 300 MG/2 ML PEN (1 PEN) has ranged from a low of $3591.8962 (Sep 18, 2024) to a high of $4105.5041 (May 13, 2026), with a median of $3843.9345 per ML.
Are there cheaper alternatives to COSENTYX UNOREADY 300 MG/2 ML PEN (1 PEN)?
No other NADAC-published product currently shares the active ingredient and strength of COSENTYX UNOREADY 300 MG/2 ML PEN (1 PEN) in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures COSENTYX UNOREADY 300 MG/2 ML PEN (1 PEN)?
COSENTYX UNOREADY 300 MG/2 ML PEN (1 PEN) (NDC 00078107068) is labeled by Novartis Pharmaceuticals Corporation, and CMS classifies it as a brand product.